International Journal of Pharmacy and Industrial Research (IJPIR)

IJPIR |Vol.15 | Issue 3 | Jul - Sept -2025

www.ijpir.com

DOI : https://doi.org/10.61096/ijpir.v15.iss3.2025.470-478

ISSN: 2231-3656
Print: 2231-3648

Review

Redefining Targeted Therapy Through Protein Degradation Using Proteolysis Targeting Chimeras

Vanitha Devi Rajendran, Guruprasath Kumar, Saifdeen Shabeer Ahamed, Abinaya Selvarasu, Balakumar Palanivelu, Vinoth Jeevanesan*

Sir Issac Newton College of Pharmacy, Nagapattinam, Tamil Nadu - 611 102, India.

*Author for Correspondence: Vinoth Jeevanesan, M.Pharm
Email: vinoth.sincop@gmail.com

Published on: 26 July 2025

Published by:
Futuristic Publications

Abstract

Proteolysis Targeting Chimeras (PROTACs) represent a novel class of heterobifunctional molecules designed to induce selective degradation of disease-associated proteins via the ubiquitin–proteasome system. Each PROTAC molecule consists of two ligands, one that binds the protein of interest and another that recruits an E3 ubiquitin ligase, connected by a flexible linker. Upon forming a ternary complex, PROTACs facilitate polyubiquitination of the target protein, marking it for degradation by the 26S proteasome. Unlike traditional inhibitors, PROTACs eliminate proteins rather than inhibit their activity, allowing them to target shallow or transient binding sites and previously "undruggable" proteins. Their catalytic mechanism enables sustained protein knockdown at substoichiometric concentrations. PROTACs are showing promising therapeutic utility, particularly in oncology, where aberrant or misfolded proteins disrupt cellular homeostasis. This review outlines the mechanistic basis of PROTAC function, highlights emerging clinical applications and discusses current challenges and future directions in advancing this transformative therapeutic strategy.

Keywords: PROTACs, Targeted Protein Degradation, Ubiquitin–Proteasome System, E3 Ligase, Catalytic Degraders, Molecular Glue, Drug Discovery.

INTRODUCTION

Targeted therapy has transformed modern medicine by enabling precise modulation of disease-related biomolecules, often with greater efficacy and fewer off-target effects than traditional therapies. Over the past two decades, small-molecule inhibitors and monoclonal antibodies have achieved notable clinical success, particularly in oncology and immunology. However, despite this progress, a large portion of the proteome remains inaccessible to conventional drug discovery strategies. These so-called "undruggable" proteins, often lacking well-defined binding pockets or possessing transient, dynamic structures, include key regulators such as transcription factors, scaffolding proteins and mutated signalling intermediates.[1] In many cases, these proteins play pivotal roles in complex diseases like cancer, neurodegenerative disorders and autoimmune conditions.

Conventional inhibitors require sustained engagement with the active site of a target protein to suppress its function, typically necessitating high systemic concentrations and increasing the risk of resistance through compensatory mutations or pathway reactivation. Moreover, these strategies offer limited control over non-catalytic or scaffolding functions of target proteins, which may still drive disease progression even when enzymatic activity is blocked.[2]

To overcome these challenges, an alternative therapeutic paradigm has emerged, targeted protein degradation (TPD). Rather than merely inhibiting protein function, TPD strategies aim to eliminate pathogenic proteins from the cellular environment altogether.[3] Among the most advanced and versatile tools in this space are Proteolysis Targeting Chimeras (PROTACs), rationally designed heterobifunctional molecules that harness the cell's ubiquitin–proteasome system (UPS) to induce selective degradation of proteins of interest.[4]

PROTACs consist of three modular components: (1) a ligand that binds the target protein, (2) a ligand that recruits an E3 ubiquitin ligase and (3) a chemical linker that bridges the two. Upon forming a ternary complex, the PROTAC brings the E3 ligase into proximity with the target protein, enabling the transfer of ubiquitin chains and marking the protein for degradation by the 26S proteasome.[5] Unlike traditional inhibitors, PROTACs function catalytically, a single molecule can trigger the degradation of multiple target proteins, resulting in durable therapeutic effects at lower doses.[6]

Beyond their catalytic mode of action, PROTACs offer several advantages: they can degrade proteins with non-enzymatic functions, overcome drug resistance due to point mutations and enable selective targeting via cooperative ternary complex formation. Additionally, their modular architecture allows for systematic optimization of pharmacological properties, target selectivity and tissue-specific delivery.

Recent advances in E3 ligase ligand discovery, linker chemistry and structural modelling have propelled PROTACs from experimental tools into clinical candidates. Several molecules, including ARV-110 (targeting the androgen receptor) and ARV-471 (targeting the estrogen receptor), are now being evaluated in human trials, marking a major milestone in the clinical validation of this platform.[7]

Mechanistic principles of protac-mediated protein degradation

Proteolysis Targeting Chimeras (PROTACs) represent a paradigm shift in targeted therapy by harnessing the cell's endogenous ubiquitin-proteasome system (UPS) to selectively degrade disease-associated proteins. This section elucidates the molecular architecture of PROTACs, the mechanistic steps of their action and the unique advantages that distinguish them from traditional therapeutic approaches.

Molecular Architecture of PROTACs

PROTACs are heterobifunctional molecules designed with three distinct components: a target-binding ligand, an E3 ligase-recruiting ligand and a chemical linker that tethers the two. The target-binding ligand is specific to the protein of interest (POI), which could range from oncogenic transcription factors to scaffolding proteins. The E3 ligase ligand recruits a component of the UPS, typically an E3 ubiquitin ligase, which is responsible for catalysing the transfer of ubiquitin to the target protein. The linker, often a flexible polyethylene glycol (PEG) or alkyl chain, spatially optimizes the interaction between the POI and the E3 ligase to facilitate efficient ubiquitin transfer.[8]

The modular nature of PROTACs allows for precise tuning of each component. For instance, the choice of E3 ligase ligand is critical, as different ligases (e.g., CRBN, VHL or IAPs) exhibit tissue-specific expression and varying efficiencies in ubiquitin transfer. Similarly, linker length and composition significantly influence the formation of a productive ternary complex, impacting the selectivity and potency of degradation.

Mechanism of Action

The PROTAC-mediated degradation process begins with the simultaneous binding of the PROTAC molecule to both the target protein and the E3 ligase, forming a ternary complex. This proximity-driven interaction enables the E3 ligase to transfer ubiquitin molecules, a small regulatory protein, to specific lysine residues on the target protein. Polyubiquitination serves as a molecular signal that directs the tagged protein to the 26S proteasome, a large multi-subunit complex that degrades ubiquitinated proteins into small peptides[9] as illustrated in figure.1.



Fig1: Mechanism of PROTACs action

A hallmark of PROTACs is their catalytic mode of action. Unlike traditional inhibitors, which require sustained occupancy of a protein's active site, a single PROTAC molecule can facilitate multiple rounds of ubiquitination and degradation. Once the target protein is marked for degradation, the PROTAC is released, allowing it to engage additional copies of the target protein. This sub-stoichiometric activity reduces the required therapeutic dose and enhances the efficiency of protein elimination.[10]

Advantages Over Traditional Inhibition

PROTACs offer several distinct advantages over conventional small-molecule inhibitors and monoclonal antibodies. First, their ability to target "undruggable" proteins expands the therapeutic landscape. Proteins lacking enzymatic activity or deep binding pockets, such as transcription factors (e.g., MYC) or scaffolding proteins (e.g., KRAS), can be effectively degraded, bypassing the limitations of traditional drug design. Second, the catalytic nature of PROTACs enables prolonged suppression of protein levels, even after the molecule is cleared from the system, reducing the risk of compensatory upregulation. Third, PROTACs can mitigate resistance mechanisms associated with traditional inhibitors, such as point mutations in the target protein, as they do not rely on functional inhibition but rather on complete protein removal.[11]

Additionally, PROTACs exhibit high selectivity, driven by the specificity of the ternary complex formation. The cooperative binding within this complex can discriminate between closely related protein isoforms, minimizing off-target effects. Advances in computational modelling and structural biology further enhance the ability to design PROTACs with optimized selectivity and pharmacokinetic profiles. The comparison between traditional inhibitors and PROTACs were summarised in Table.1.

Table 1: Comparison Between Traditional Inhibitors and PROTACs

Parameter	Traditional Inhibitors	PROTACs
Mechanism	Occupancy-driven inhibition	Event-driven degradation
Protein Requirement	Enzymatic active site	Any surface binding site
Duration of Action	Requires sustained binding	Catalytic, prolonged effect
Resistance Susceptibility	High (mutations in active site)	Lower (acts post-binding)
Scope	Druggable proteome (~15%)	Potential access to undruggable proteins
Dosage Requirement	Higher	Lower
Functional Elimination	Partial	Complete

Challenges in Mechanistic Optimization

Despite their promise, PROTAC design and function face several mechanistic challenges. The formation of a stable and productive ternary complex is highly sensitive to linker length, composition and the choice of E3 ligase. Inefficient complex formation can lead to reduced degradation efficiency or unintended degradation of non-target proteins. Additionally, the tissue-specific expression of E3 ligases can limit the applicability of certain PROTACs in specific disease contexts. The pharmacokinetic properties of PROTACs, including their stability and cell permeability, also require careful optimization to ensure effective delivery to the target tissue.[12]

In summary, the mechanistic principles of PROTAC-mediated protein degradation hinge on their ability to co-opt the UPS for selective protein elimination. Their modular design, catalytic action and capacity to target previously undruggable proteins position PROTACs as a transformative tool in drug development. Ongoing research into E3 ligase diversity, linker chemistry and computational design continues to refine their mechanistic efficiency, paving the way for broader therapeutic applications.

Therapeutic applications and clinical progress of protacs

Proteolysis Targeting Chimeras (PROTACs) have transitioned from an innovative concept to a promising therapeutic platform, demonstrating significant potential across a range of diseases. By enabling the selective degradation of disease-causing proteins, PROTACs offer a novel approach to addressing previously intractable targets. This section examines the therapeutic applications of PROTACs, with a focus on their impact in oncology, emerging applications in other disease areas and the current state of clinical development.

PROTACs in Oncology

The majority of PROTAC development has cantered on oncology, where the ability to degrade oncogenic proteins has transformative potential. Many cancers are driven by proteins that are challenging to target with conventional therapies, such as transcription factors, scaffolding proteins or mutated signalling molecules. PROTACs have shown remarkable efficacy in preclinical models by targeting key oncogenic drivers, including the androgen receptor (AR) in prostate cancer, the estrogen receptor (ER) in breast cancer and bromodomain-containing protein 4 (BRD4) in various hematologic and solid tumours.

For example, AR-targeting PROTACs, such as ARV-110, have demonstrated potent degradation of AR in preclinical models of castration-resistant prostate cancer (CRPC). Similarly, ER-targeting PROTACs, like ARV-471, have shown promise in ER-positive breast cancer by achieving sustained degradation of ER and inhibiting tumour growth. BRD4, a key epigenetic regulator in cancers like acute myeloid leukaemia (AML), has also been effectively targeted by PROTACs, leading to robust tumour suppression in preclinical studies. These successes are attributed to the ability of PROTACs to eliminate the entire protein, including its scaffolding and non-enzymatic functions, which are often critical to cancer progression but resistant to traditional inhibition.[13]

Emerging Applications Beyond Oncology

While oncology remains the primary focus, the versatility of PROTACs is driving exploration into other therapeutic areas, including neurodegeneration, autoimmune disorders and infectious diseases. In neurodegenerative diseases, such as Alzheimer's and Parkinson's, PROTACs offer a strategy to degrade misfolded or aggregated proteins, such as tau or alpha-synuclein, which are implicated in disease pathology. Preclinical studies have demonstrated the feasibility of PROTACs in crossing the blood-brain barrier and achieving selective degradation of these targets, though challenges in delivery and specificity remain.[14]

In autoimmune disorders, PROTACs targeting pro-inflammatory signalling molecules, such as interleukin-1 receptor-associated kinase 4 (IRAK4), have shown potential in modulating immune responses.[15] Similarly, in infectious diseases, PROTACs are being investigated for their ability to degrade pathogen-derived proteins or host factors critical to viral replication, offering a novel approach to antiviral therapy.[16] These emerging applications highlight the broad applicability of PROTAC technology, enabled by its ability to target diverse protein classes across various cellular contexts.

Clinical Progress and Key Candidates

The clinical translation of PROTACs has gained significant momentum, with several candidates advancing into human trials, primarily in oncology. ARV-110 (targeting AR) and ARV-471 (targeting ER), developed by Arvinas, were among the first PROTACs to enter clinical trials, demonstrating favourable safety profiles and preliminary evidence of efficacy in patients with CRPC and ER-positive breast cancer, respectively. These trials have validated the feasibility of PROTAC-mediated degradation in humans, showing that these molecules can achieve sustained target protein reduction in vivo.[17]

Other notable clinical candidates include PROTACs targeting BRD4, BCL-2 and Bruton's tyrosine kinase (BTK), which are being evaluated in hematologic malignancies and solid tumours. The clinical success of these candidates depends on optimizing pharmacokinetic properties, such as oral bioavailability and tissue penetration, as well as minimizing off-target effects. Advances in E3 ligase ligand discovery and linker

optimization have further expanded the repertoire of targetable proteins, fuelling the development of next-generation PROTACs with improved specificity and potency.[18]

Impact on Targeted Therapy

The advent of PROTACs is redefining targeted therapy by expanding the druggable proteome and overcoming limitations of traditional inhibitors. Their ability to degrade non-enzymatic proteins and achieve catalytic activity offers a more durable therapeutic effect compared to conventional drugs, which often require high doses and continuous target engagement. Moreover, PROTACs can address resistance mechanisms, such as mutations that render proteins insensitive to inhibitors, by eliminating the protein entirely. This capability is particularly valuable in cancers with high mutational burdens, where resistance is a major clinical challenge.[19]

The modular design of PROTACs also facilitates rapid development and optimization, enabling researchers to tailor molecules for specific diseases or patient populations. The integration of computational tools, such as molecular dynamics simulations and machine learning, has further accelerated the design of PROTACs with enhanced selectivity and pharmacokinetic profiles, paving the way for personalized medicine applications.

Challenges in Clinical Translation

Despite their promise, the clinical development of PROTACs faces several challenges. The large molecular weight of PROTACs can limit their cell permeability and bioavailability, necessitating innovative delivery strategies. Additionally, the reliance on specific E3 ligases, which may have variable expression across tissues or patients, can affect therapeutic efficacy. Off-target degradation, driven by non-specific ternary complex formation, remains a concern, underscoring the need for rigorous selectivity profiling. Finally, long-term safety data are still emerging, particularly regarding the potential for immune-related or proteasome-overload toxicities.[20]

In conclusion, PROTACs have opened new frontiers in targeted therapy by enabling the degradation of previously undruggable proteins. Their success in oncology and emerging applications in other disease areas highlight their transformative potential. As clinical trials progress and new PROTAC candidates emerge, continued advancements in molecular design and delivery strategies will be critical to realizing their full therapeutic impact.

Challenges and future directions in protac development

While Proteolysis Targeting Chimeras (PROTACs) have demonstrated remarkable potential in redefining targeted therapy, several challenges impede their widespread clinical adoption. These include limitations in molecular design, pharmacokinetic properties and biological complexities of the ubiquitin-proteasome system (UPS). This section explores the primary hurdles in PROTAC development and highlights emerging strategies to address these challenges, paving the way for next-generation protein degradation therapies.

Technical Challenges in PROTAC Design

The heterobifunctional nature of PROTACs, which combine a target-binding ligand, an E3 ligase-recruiting ligand and a chemical linker, introduces significant complexity in molecular design. One major challenge is optimizing the linker to ensure efficient ternary complex formation between the target protein and the E3 ligase. Suboptimal linker length or composition can result in weak or unstable complexes, reducing degradation efficiency or leading to off-target effects. Additionally, the large molecular weight of PROTACs, often exceeding 1,000 Da, can limit cell permeability, oral bioavailability and tissue distribution, particularly for targets in challenging environments like the central nervous system.[21]

Another technical hurdle is the limited repertoire of E3 ligase ligands. The human genome encodes over 600 E3 ligases, yet only a small subset, such as CRBN, VHL and IAPs, are commonly exploited in PROTAC design. This reliance restricts the applicability of PROTACs in tissues with low expression of these ligases and may contribute to variable therapeutic outcomes across patient populations. Furthermore, the development of high-affinity, selective ligands for novel E3 ligases remains a significant bottleneck, requiring advances in chemical biology and high-throughput screening.[22]

Biological and Pharmacological Challenges

The biological complexity of the UPS poses additional challenges. The efficiency of PROTAC-mediated degradation depends on the cellular context, including the expression levels and activity of E3 ligases, the availability of the 26S proteasome and the target protein's turnover rate. Variations in these factors across cell types, tissues or disease states can lead to inconsistent degradation outcomes. For instance, cancer cells with high proteasome activity may respond more robustly to PROTACs, whereas cells with compromised UPS function may exhibit reduced efficacy.[23]

Resistance mechanisms also present a significant challenge. While PROTACs can overcome resistance associated with target protein mutations, alternative resistance pathways, such as upregulation of anti-apoptotic

proteins, mutations in E3 ligases or alterations in proteasome function, have been observed in preclinical models. These mechanisms underscore the need for combination therapies and predictive biomarkers to identify patients likely to benefit from PROTAC-based treatments.[24]

Long-term safety remains a critical concern. Chronic protein degradation may disrupt cellular homeostasis, potentially leading to proteasome overload, accumulation of misfolded proteins or immune-related toxicities. The off-target degradation of non-intended proteins, driven by non-specific ternary complex formation, further complicates safety profiles. Comprehensive toxicological studies and advanced selectivity profiling are essential to mitigate these risks.[25]

Future Directions in PROTAC Development

To address these challenges, several innovative strategies are being pursued to enhance PROTAC technology. Advances in computational modelling, such as molecular dynamics simulations and machine learning, are improving the rational design of PROTACs. These tools enable the prediction of ternary complex stability, linker optimization and ligand selectivity, streamlining the development process. Structure-based drug design, informed by cryo-electron microscopy and X-ray crystallography, is also facilitating the discovery of novel E3 ligase ligands, expanding the degradable proteome.[26]

The exploration of alternative degradation pathways offers another avenue for innovation. For example, molecular glues, which enhance the affinity between an E3 ligase and a target protein without a linker, provide a complementary approach to PROTACs. Additionally, lysosome-targeting chimeras (LYTACs) and autophagy-targeting chimeras (AUTACs) are being developed to degrade extracellular or membrane-bound proteins, broadening the scope of targeted protein degradation beyond the UPS.[27]

Improving pharmacokinetic properties is a priority for clinical translation. Strategies such as prodrug approaches, nanoparticle-based delivery systems and chemical modifications to enhance solubility and stability are being explored to improve PROTAC bioavailability and tissue penetration.[28] For instance, encapsulation in lipid nanoparticles has shown promise in enhancing delivery to specific tissues, including the brain, for neurodegenerative applications.

Combination therapies represent a promising future direction. Pairing PROTACs with small-molecule inhibitors, immunotherapies or other degraders could overcome resistance mechanisms and enhance therapeutic efficacy. For example, combining PROTACs with kinase inhibitors may prevent pathway reactivation in cancer, while synergistic combinations with immune checkpoint inhibitors could amplify anti-tumour immune responses.[29]

Finally, the development of biomarkers and companion diagnostics will be critical for patient stratification and treatment optimization. Identifying predictors of PROTAC efficacy, such as E3 ligase expression levels or proteasome activity, will enable personalized approaches to therapy. Advances in proteomics and single-cell sequencing are providing insights into the cellular factors that influence PROTAC performance, guiding the design of tailored therapeutic strategies.[30]

The challenges in PROTAC development, ranging from molecular design to biological complexities, highlight the need for interdisciplinary approaches to advance this technology. By leveraging innovations in computational design, novel degradation pathways and optimized delivery systems, the field is poised to overcome current limitations. The continued evolution of PROTACs, coupled with strategic combination therapies and personalized medicine approaches, will further redefine targeted therapy, unlocking new possibilities for treating complex diseases.

Protacs in the context of targeted protein degradation

Proteolysis Targeting Chimeras (PROTACs) have emerged as a groundbreaking platform in targeted therapy, fundamentally reshaping the approach to drug development by enabling the selective degradation of disease-associated proteins. This section discusses the broader implications of PROTACs within the evolving field of targeted protein degradation (TPD), compares PROTACs with other TPD technologies and reflects on their transformative potential in the context of modern drug discovery.

PROTACs as a Cornerstone of Targeted Protein Degradation

The advent of PROTACs has expanded the druggable proteome by addressing proteins previously considered intractable, such as non-enzymatic proteins, transcription factors and scaffolding molecules. Unlike traditional small-molecule inhibitors, which rely on sustained target occupancy to inhibit function, PROTACs operate through a catalytic, event-driven mechanism that eliminates the target protein entirely. This paradigm shift not only enhances therapeutic efficacy but also mitigates resistance mechanisms, such as target mutations or pathway reactivation, that limit the durability of conventional therapies. The clinical success of PROTACs, such as ARV-110 and ARV-471 in oncology, underscores their potential to address unmet medical needs in diseases driven by complex proteinopathies.[31]

The modular design of PROTACs, comprising a target-binding ligand, an E3 ligase-recruiting ligand and a chemical linker, offers unparalleled flexibility in drug design. This modularity allows researchers to

systematically optimize selectivity, potency and pharmacokinetic properties, tailoring molecules to specific disease contexts. Furthermore, the ability of PROTACs to degrade multiple copies of a target protein with a single molecule reduces the required therapeutic dose, potentially improving safety profiles and patient compliance.[32]

Comparison with Other Targeted Protein Degradation Technologies

While PROTACs are a leading TPD technology, they are part of a broader ecosystem of degradation-based approaches, including molecular glues, lysosome-targeting chimeras (LYTACs) and autophagy-targeting chimeras (AUTACs). Molecular glues, for instance, enhance the affinity between an E3 ligase and a target protein without the need for a linker, offering a smaller molecular footprint and improved pharmacokinetic properties. However, molecular glues lack the modular tunability of PROTACs and are often discovered serendipitously, limiting their rational design.[33]

LYTACs, which leverage the lysosomal degradation pathway, enable the targeting of extracellular and membrane-bound proteins, complementing the intracellular focus of PROTACs. Similarly, AUTACs exploit autophagy to degrade protein aggregates and cellular organelles, offering potential in neurodegenerative diseases where PROTACs may face delivery challenges. Each of these technologies has unique strengths, but PROTACs stand out for their versatility, catalytic efficiency and ability to target a wide range of intracellular proteins.[34]

The choice between PROTACs and other TPD approaches depends on the therapeutic context, including the nature of the target protein, its cellular localization and the disease environment. Integrating these technologies into a cohesive TPD platform could enable comprehensive targeting of the proteome, combining the strengths of UPS-, lysosome- and autophagy-based degradation strategies.[35]

Broader Implications for Drug Discovery

The rise of PROTACs reflects a broader trend in drug discovery toward event-driven pharmacology, where therapeutic effects are achieved through transient molecular interactions rather than prolonged target inhibition. This shift has profound implications for addressing complex diseases, such as cancers with high mutational burdens or neurodegenerative disorders driven by protein aggregation. By enabling the degradation of previously undruggable targets, PROTACs are expanding the therapeutic landscape and fostering the development of precision medicine approaches tailored to individual patient profiles.[36]

The integration of advanced technologies, such as artificial intelligence, structural biology and high-throughput screening, is accelerating PROTAC development. Machine learning models can predict ternary complex stability and optimize linker design, while cryo-electron microscopy provides insights into the structural dynamics of PROTAC-mediated interactions. These tools, combined with proteomic and genomic profiling, are enabling the identification of novel targets and E3 ligases, further broadening the applicability of PROTACs.[37]

Societal and Ethical Considerations

As PROTACs advance toward widespread clinical use, their impact extends beyond scientific and medical domains to societal and ethical considerations. The high cost of developing and manufacturing complex heterobifunctional molecules may limit access to PROTAC-based therapies, raising questions about equitable healthcare distribution. Additionally, the long-term effects of sustained protein degradation, particularly in non-disease contexts, warrant careful evaluation to ensure safety and minimize unintended consequences.[38] The development of robust regulatory frameworks and standardized safety protocols will be essential to guide the ethical deployment of PROTACs.

Perspectives on the Future of PROTACs

The future of PROTACs lies in their ability to integrate with other therapeutic modalities and adapt to emerging scientific and clinical challenges. Combination therapies, pairing PROTACs with immunotherapies, small-molecule inhibitors or gene therapies, hold promise for overcoming resistance and enhancing efficacy. The development of tissue-specific E3 ligase ligands and advanced delivery systems, such as nanoparticle-based carriers, will improve the precision and reach of PROTACs, particularly in challenging tissues like the brain.

Moreover, the application of PROTACs in personalized medicine is a compelling frontier. By leveraging biomarkers, such as E3 ligase expression or proteomic signatures, clinicians can identify patients most likely to benefit from PROTAC therapies, optimizing treatment outcomes. The continued expansion of the TPD field, driven by interdisciplinary collaboration and technological innovation, will solidify PROTACs as a cornerstone of next-generation drug discovery.[39]

PROTACs represent a transformative leap in targeted therapy, bridging the gap between the undruggable proteome and effective clinical intervention. Their integration with other TPD technologies, coupled with advances in design and delivery, positions PROTACs at the forefront of precision medicine. As the field evolves, PROTACs will continue to redefine the boundaries of therapeutic possibility, offering new hope for patients with complex and previously intractable diseases.

CONCLUSION

Proteolysis Targeting Chimeras (PROTACs) have ushered in a new era of targeted therapy by offering a revolutionary approach to selectively eliminate disease-causing proteins. By harnessing the cell's ubiquitin-proteasome system, PROTACs overcome the limitations of traditional inhibitors, enabling the degradation of previously "undruggable" targets such as transcription factors, scaffolding proteins and mutated signalling molecules. Their catalytic mechanism, modular design and ability to address resistance mechanisms have positioned PROTACs as a transformative platform in drug development, with significant implications for precision medicine.

The mechanistic elegance of PROTACs lies in their ability to form ternary complexes that facilitate precise ubiquitin-mediated degradation, offering advantages over conventional therapies in terms of potency, selectivity and durability. In oncology, PROTACs targeting proteins like the androgen receptor, estrogen receptor and BRD4 have demonstrated clinical promise, with candidates like ARV-110 and ARV-471 paving the way for broader therapeutic applications. Beyond cancer, emerging applications in neurodegenerative diseases, autoimmune disorders and infectious diseases underscore the versatility of this technology, expanding the boundaries of the druggable proteome.

Despite their potential, PROTACs face challenges related to molecular design, pharmacokinetic optimization and biological variability. The large molecular weight of PROTACs, limited repertoire of E3 ligase ligands and tissue-specific expression of UPS components necessitate ongoing innovation in linker chemistry, ligand discovery and delivery systems. Advances in computational modelling, alternative degradation pathways (e.g., LYTACs and molecular glues) and combination therapies are addressing these hurdles, enhancing the efficacy and applicability of PROTACs. Moreover, the integration of biomarkers and companion diagnostics promises to enable personalized treatment strategies, ensuring optimal therapeutic outcomes.

Looking forward, PROTACs are poised to redefine the landscape of targeted therapy. Their ability to target a wide range of proteins, coupled with their potential for synergistic combinations with existing therapies, positions them as a cornerstone of next-generation precision medicine. The continued development of novel E3 ligase ligands, improved delivery mechanisms and robust safety profiles will be critical to realizing their full therapeutic potential. As clinical trials progress and new applications emerge, PROTACs are likely to transform the treatment of complex diseases, offering hope for patients with conditions previously considered intractable.

In conclusion, PROTAC-mediated protein degradation represents a paradigm shift in drug development, bridging the gap between the undruggable proteome and effective therapeutic intervention. By combining mechanistic innovation with clinical translation, PROTACs are not only redefining targeted therapy but also shaping the future of medicine, where precision, efficacy and adaptability converge to address unmet medical needs.

REFERENCES

1. Zhang G, Zhang J, Gao Y, Li Y, Li Y. Strategies for targeting undruggable targets. Expert Opin Drug Discov 2022;17(1):55–69.
2. Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. Nat Rev Drug Discov 2018;17(5):353–77.
3. Tsai JM, Nowak RP, Ebert BL, Fischer ES. Targeted protein degradation: from mechanisms to clinic. Nat Rev Mol Cell Biol 2024;25(9):740–57.
4. Liang X, Ren H, Han F, Liang R, Zhao J, Liu H. The new direction of drug development: Degradation of undruggable targets through targeting chimera technology. Med Res Rev 2024;44(2):632–85.
5. Li K, Crews CM. PROTACs: past, present and future. Chem Soc Rev 2022;51(12):5214–36.
6. Békés M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov 2022;21(3):181–200.
7. Du W. Targeted Protein Degradation by Proteolysis Targeting Chimeras: A Revolution in Small Molecule Drug Discovery. Contemporary Accounts in Drug Discovery and Development 2022;225–71.
8. Ermondi G, Garcia-Jimenez D, Caron G. Protacs and building blocks: The 2d chemical space in very early drug discovery. Molecules 2021;26(3):672.
9. Faust TB, Donovan KA, Yue H, Chamberlain PP, Fischer ES. Small-molecule approaches to targeted protein degradation. Annu Rev Cancer Biol 2021;5(1):181–201.
10. Sun X, Gao H, Yang Y, He M, Wu Y, Song Y, et al. PROTACs: great opportunities for academia and industry. Signal Transduct Target Ther 2019;64(4):1–33.
11. Liu Z, Hu M, Yang Y, Du C, Zhou H, Liu C, et al. An overview of PROTACs: a promising drug discovery paradigm. Molecular biomedicine 2022;3(46):1–26.
12. Gao H, Sun X, Rao Y. PROTAC technology: opportunities and challenges. ACS Med Chem Lett 2020;11(3):237–40.

13. Sowndharya M, Joga R, Gandhi K, Yerram S, Raghuvanshi RS, Srivastava S. Exploring the clinical trials, regulatory insights, and challenges of PROTACs in oncology. In: Seminars in Oncology. Elsevier; 2025. page 152339.
14. Kong D, Meng L, Lin P, Wu G. Advancements in PROTAC-based therapies for neurodegenerative diseases. Future Med Chem 2025;17(5):591–605.
15. Feng Y, Chen C, Shao A, Zhang Q, Sun L, Hu HY, et al. Recent advances in interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and PROTACs. Chinese Chemical Letters 2025;110963.
16. Grohmann C, Marapana DS, Ebert G. Targeted protein degradation at the host–pathogen interface. Mol Microbiol 2022;117(3):670–81.
17. Salama AKAA, Trkulja M V, Casanova E, Uras IZ. Targeted protein degradation: clinical advances in the field of oncology. Int J Mol Sci 2022;23(23):15440.
18. He Y, Khan S, Huo Z, Lv D, Zhang X, Liu X, et al. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies. J Hematol Oncol 2020;13(103):1–24.
19. Neklesa TK, Winkler JD, Crews CM. Targeted protein degradation by PROTACs. Pharmacol Ther 2017;174:138–44.
20. Chen Y, Tandon I, Heelan W, Wang Y, Tang W, Hu Q. Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation. Chem Soc Rev 2022;51(13):5330–50.
21. Guedeney N, Cornu M, Schwalen F, Kieffer C, Voisin-Chiret AS. PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery. Drug Discov Today 2023;28(1):103395.
22. Ishida T, Ciulli A. E3 ligase ligands for PROTACs: how they were found and how to discover new ones. SLAS DISCOVERY: Advancing the Science of Drug Discovery 2021;26(4):484–502.
23. Saraswat AL, Vartak R, Hegazy R, Patel A, Patel K. Drug delivery challenges and formulation aspects of proteolysis targeting chimera (PROTACs). Drug Discov Today 2023;28(1):103387.
24. Abbas R, Larisch S. Killing by degradation: regulation of apoptosis by the ubiquitin-proteasome-system. Cells 2021;10(12):3465.
25. Beling A, Kespohl M. Proteasomal protein degradation: adaptation of cellular proteolysis with impact on virus—and cytokine-mediated damage of heart tissue during myocarditis. Front Immunol 2018;9:2620.
26. Troup RI, Fallan C, Baud MGJ. Current strategies for the design of PROTAC linkers: a critical review. Explor Target Antitumor Ther 2020;1(5):273.
27. Paudel RR, Lu D, Roy Chowdhury S, Monroy EY, Wang J. Targeted protein degradation via lysosomes. Biochemistry 2022;62(3):564–79.
28. Mustafa S, Siddiquee MSH. PROTACs: Mechanism and bioavailability enhancement strategies by nanotechnology, RNA viral infections (vaccine strategy) and prodrug development. German Journal of Pharmaceuticals and Biomaterials 2024;3(4):1–22.
29. Ahn R, Ursini-Siegel J. Clinical potential of kinase inhibitors in combination with immune checkpoint inhibitors for the treatment of solid tumors. Int J Mol Sci 2021;22(5):2608.
30. Danishuddin, Jamal MS, Song KS, Lee KW, Kim JJ, Park YM. Revolutionizing drug targeting strategies: integrating artificial intelligence and structure-based methods in PROTAC development. Pharmaceuticals 2023;16(12):1649.
31. Dubey A, Pal K, Gota V. Clinical Development of PROTACs. In: PROTAC-Mediated Protein Degradation: A Paradigm Shift in Cancer Therapeutics. Springer; 2024. page 169–92.
32. Li K, Crews CM. PROTACs: past, present and future. Chem Soc Rev 2022;51(12):5214–36.
33. Wang H, Zhou R, Xu F, Yang K, Zheng L, Zhao P, et al. Beyond canonical PROTAC: biological targeted protein degradation (bioTPD). Biomater Res 2023;27(1):72.
34. Li Y yang, Yang Y, Zhang R shuai, Ge R xin, Xie S bo. Targeted degradation of membrane and extracellular proteins with LYTACs. Acta Pharmacol Sin 2025;46(1):1–7.
35. Cassidy K, Zhao H. Redefining the scope of targeted protein degradation: translational opportunities in hijacking the autophagy–lysosome pathway. Biochemistry 2021;62(3):580–7.
36. Mahajan A, Panzade G, Bhuniya T, Das P, Bhattacharjee B, Das S, et al. Revolutionizing lung cancer treatment: Introducing PROTAC therapy as a novel paradigm in targeted therapeutics. Curr Probl Cancer 2025;54:101172.
37. Troup RI, Fallan C, Baud MGJ. Current strategies for the design of PROTAC linkers: a critical review. Explor Target Antitumor Ther 2020;1(5):273.
38. Corson TW, Aberle N, Crews CM. Design and applications of bifunctional small molecules: why two heads are better than one. ACS Chem Biol 2008;3(11):677–92.
39. Nalawansha DA, Crews CM. PROTACs: an emerging therapeutic modality in precision medicine. Cell Chem Biol 2020;27(8):998–1014.